Abstract
In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830 .
Keywords: CCR5; immunosuppression; leronlimab; long COVID.
All Keywords
【저자키워드】 Immunosuppression, CCR5, Leronlimab, long COVID., 【초록키워드】 Trial, antibody, immune, COVID, Registration, symptomatic, clinical, Responder, exploratory, mechanism, Blood, Cell, placebo-treated participants, significantly increased, treated, normalized, 【제목키워드】 surface, Long, Level,
【저자키워드】 Immunosuppression, CCR5, Leronlimab, long COVID., 【초록키워드】 Trial, antibody, immune, COVID, Registration, symptomatic, clinical, Responder, exploratory, mechanism, Blood, Cell, placebo-treated participants, significantly increased, treated, normalized, 【제목키워드】 surface, Long, Level,